Gavin Dunn, MD, PhD | MGH Research Scholar Profile
MGH Research Scholars Program
The MGH Research Scholars Program was established to support early career researchers with innovative yet unproven ideas that have the potential to transform the future of medicine. Funded 100% through philanthropy, this program gives researchers the freedom and flexibility they need to follow the science wherever it leads. History has shown that brilliant scientists who are given free rein to explore new frontiers make the greatest, often unexpected, advances.
Understanding Immune Responses to Brain Tumors to Improve Glioblastoma Treatment
Glioblastoma (GBM) is the most frequently diagnosed brain cancer and remains incurable despite aggressive surgical resection followed by radiation treatment and chemotherapy.
Incredibly, as treatment strategies for other cancers have evolved with cutting edge precision medicine and/or immune-based treatments, the standard of care for GBM has not changed in over 18 years.
It is especially notable that, as immunotherapy has had a seismic influence on oncology and changed cancer care within the last decade, there remain no FDA approved immunotherapies for GBM.
Our motivating premise is that we can advance brain tumor immunotherapy if we better understand how the immune response in the central nervous system (CNS) is supposed to work.
Unlike other locations in the body, the CNS is immunologically specialized, and thus understanding how immune responses develop to cancers in this location is imperative.
In particular, we are interested in the following key questions in the brain tumor immunity cycle:
- How does the immune system become aware there is a tumor growing in the brain?
- How do brain tumor antigens transit, and how and where are they presented?
- What are the antigens recognized by tumor-specific T cells?
- How can we direct T cells to attack brain tumor cells in patients?
More recently, we have also become interested in how neurons and the tissue-specific signals in the CNS ecosystem influence how the immune system sees brain tumors.
As our program continues to evolve, our goal is to translate our understanding of the unique features of the immune response in the CNS to patients.
The Mass General ethos of excellent patient care synergizing with world-class research has always inspired me. I am thrilled and humbled by this award, which will accelerate our work to better understand the immune response to brain tumors and, hopefully, lead to new insights that translate into therapies for our patients.
Gavin Dunn, MD, PhD
Paul B. and Sandra M. Edgerley MGH Research Scholar 2024-2029
53 Mass General Investigators Named Highly Cited Researchers of 2023
According to Clarivate Analytics’ Highly Cited Researchers Report
Check out the Mass General Research Institute blog
Bench Press highlights the groundbreaking research and boundary-pushing scientists working to improve human health and fight disease.
Meet the 2024-2029 MGH Research Scholars
The MGH Research Scholars in the class of 2024-2029 include investigators working to solve key challenges in endocrinology, pathology, obstetrics and maternal health, genetics and cancer.